Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) jumped 5.05% in pre-market trading on Thursday, following the release of positive Phase 2 data for its lead drug candidate REC-994 in treating cerebral cavernous malformations (CCM).
The company reported that in the Phase 2 SYCAMORE study, REC-994 met the primary endpoint of safety and tolerability, with no treatment-related discontinuations or Grade 3 adverse events. More importantly, the 400mg dose showed promising trends in reducing total lesion volume and improving functional outcomes as measured by the modified Rankin Scale (mRS). These positive signals were observed in both the overall study population and the subset of patients with brainstem lesions, representing a high unmet medical need.
Based on these encouraging results, Recursion plans to submit the data for publication in a peer-reviewed journal and engage in regulatory discussions on the next development steps for REC-994. The company also has an ongoing long-term extension study to gather additional data on REC-994's efficacy and safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.